BriaCell Therapeutics Corp.

TSX (CAD): BriaCell Therapeutics Corp. (BCT)

Last Price

7.05

Today's Change

-0.175 (2.42%)

Day's Change

6.90 - 10.70

Trading Volume

75,183

Overview

Market Cap

22 Million

Shares Outstanding

2 Million

Avg Volume

5,414

Avg Price (50 Days)

13.27

Avg Price (200 Days)

20.06

PE Ratio

-0.39

EPS

-19.23

Earnings Announcement

17-Mar-2025

Previous Close

7.23

Open

9.32

Day's Range

6.9 - 10.7

Year Range

6.9 - 86.85

Trading Volume

75,483

Price Change Highlight

1 Day Change

3.73%

5 Day Change

-6.48%

1 Month Change

-46.24%

3 Month Change

-54.55%

6 Month Change

-46.81%

Ytd Change

-39.02%

1 Year Change

-90.49%

3 Year Change

-93.89%

5 Year Change

-97.87%

10 Year Change

-98.99%

Max Change

-99.83%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment